Literature DB >> 31580171

Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia - real-world resource use data.

Catherine S Y Lecat1, Caroline Besley2, Rachael E Hough1, Asim Khwaja3, Caroline Furness2, David I Marks2, Adele K Fielding3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31580171     DOI： 10.1080/10428194.2019.1672057

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  1 in total

1.  Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden.

Authors:  I van Oostrum; T A Russell-Smith; M Jakobsson; J Torup Østby; B Heeg
Journal:  Pharmacoecon Open       Date:  2021-07-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.